The Royal Marsden Hospital

We are very grateful to Breast Cancer Research Aid for your support of The Royal Marsden’s C-TRAK trial, an innovative research project that has the potential to change the lives of women diagnosed with triple negative breast cancer in the UK and world-wide.

The Royal Marsden was founded thanks to contemporary philanthropists and your generosity is continuing this important tradition. Thank you for helping us to drive forward advances in breast cancer research and provide patients with the best quality of life.

C-TRAK: Developing a novel way to detect and treat breast cancer
Breast cancer is the most common cancer in the UK, with around 55,000 women diagnosed every year. Of those women, 15 per cent will be diagnosed with triple negative breast cancer (TNBC).

Standard treatment for this type of cancer includes surgery and chemotherapy. However, TNBC is difficult to treat because it does not respond to common therapies, such as tamoxifen or Herceptin.

Furthermore, TNBC is more likely to recur than other breast cancers. Sadly, by the time TNBC returns and has grown large enough to be seen on a CT or MRI scan, the disease is often untreatable.

To meet this challenge, The Royal Marsden is leading C-TRAK: a two-part clinical trial that will assess if a blood test can detect TNBC as soon as it recurs and investigate a new therapy option to successfully treat the disease before it becomes life-threatening.

Read More…

Read more

The Institute Of Cancer Research (ICR), London

Breast Cancer Research Aid’s support of the work carried out at The Institute of Cancer Research, London, helps ensure discoveries made in our laboratories lead to new treatments for breast cancer. At the ICR we discover new cancer drugs and combination therapies.

We uncover new insights into the causes of breast cancer and how it becomes resistant to treatment, and we develop novel ways to image tumors. But to embark on our innovative research, we need your support. This is where Breast Cancer Research Aid plays such an important role.

Through your funding, our scientists are able to continue their research with access to the latest technology and cutting-edge infrastructure. This will allow them to continue making significant steps towards improving the lives of breast cancer patients around the world.

Read more: ICR’s research into liquid biopsy tests

Read more

Cardiff University/European Cancer Stem Cell Research Institute

Cardiff University/European Cancer Stem Cell Research Institute is leading the way in using stem cell research to develop new cancer therapies.

The Institute offers a state-of-the-art research environment for world-leading specialist researchers, senior academics, research fellows and postgraduate students to interact. It is a hub of research excellence in targeting cancer.

There is growing evidence that cancer stem cells are crucial to the formation of tumours. By selectively eliminating the cancer stem cells within a tumour, rather than attacking all of the tumour cells, it should be possible to treat cancer more effectively.

However, there is so much more we need to learn about cancer stem cells. Cancer stem cells have already been shown to be capable of initiating leukaemia, and work at the Institute shows they also play a role in the onset of skin cancer. However, the situation with other types of cancer is much less clear.

Find out more about the work the Institute is doing on breast cancer research.

Find out more about the European Cancer Stem Cell Research Institute.

Read more